Pd52-06 Testosterone Therapy in Women Is Not Associated With Increased Cardiovascular Risk—a Us Claims Database Analysis

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (PD52)1 May 2024PD52-06 TESTOSTERONE THERAPY IN WOMEN IS NOT ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK—A US CLAIMS DATABASE ANALYSIS Jessica Y. Hsueh, Pranjal Agrawal, Sajya M. Singh, Jaden Kohn, Marisa Clifton, and Taylor Kohn Jessica Y. HsuehJessica Y. Hsueh , Pranjal AgrawalPranjal Agrawal , Sajya M. SinghSajya M. Singh , Jaden KohnJaden Kohn , Marisa CliftonMarisa Clifton , and Taylor KohnTaylor Kohn View All Author Informationhttps://doi.org/10.1097/01.JU.0001009412.04863.1b.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Testosterone therapy (TTh) can improve libido for women with sexual dysfunction. TTh has been associated with increased cardiovascular risks in men but not well-studied in women. Our study evaluates the association of TTh in women with major adverse cardiac events (MACE), including heart attack, stroke, and death. METHODS: A large electronic medical record and claims database, TriNetX Diamond Network, was queried to identify adult women with >3 testosterone prescriptions within a year for our study cohort. Our control cohort excluded women with testosterone prescriptions, polycystic ovary syndrome, or androgen excess. Both cohorts were propensity-matched and excluded women with prior heart failure, unstable angina, intersex surgery female to male, personal history of sex reassignment, or gender identity disorders. We assessed the association of TTh to MACE, upper or lower emboli or deep vein thrombosis (DVT), pulmonary embolism (PE), breast neoplasm, and hirsutism within three years of initiating TTh. Age-based sub-analysis (18-55-year-old and 56+ year-old) was also conducted. RESULTS: After matching, the average age of women with TTh was 43.9±15.3 years and 44.4±16.3 years in our control group. Adult women with TTh had significantly lower risk of MACE (RR 0.64, 0.51 – 0.81), upper or lower emboli or DVT (RR 0.61, 0.42 - 0.90), PE (RR 0.48, 0.28 – 0.82), and malignant breast neoplasm (RR 0.48, 0.37 – 0.62). Women aged 18-55 also had lower risk of MACE (RR 0.49, 0.28 – 0.85) and upper or lower emboli or DVT (RR 0.48, 0.25 – 0.93) and similar risk of malignant breast neoplasm (RR 0.62, 0.34 – 1.12). Women aged 56+ had similar risk of MACE (RR 0.84, 0.64 – 1.10), upper or lower emboli or DVT (RR 0.82, 0.50 – 1.36), and PE (RR 0.52, 0.26 – 1.05), and significantly lower risk of malignant breast neoplasm (RR 0.51, 0.38 – 0.68). Risk of hirsutism was consistently higher in those with TTh. CONCLUSIONS: Our study contributes to TTh safety data in women by showing no increased risk of MACE or breast cancer among women initiating TTh. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1074 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jessica Y. Hsueh More articles by this author Pranjal Agrawal More articles by this author Sajya M. Singh More articles by this author Jaden Kohn More articles by this author Marisa Clifton More articles by this author Taylor Kohn More articles by this author Expand All Advertisement PDF downloadLoading ...